In this study, we carried out a proteomic analysis on HER2-overexpressing human breast cancer (BC) spheroids, as responders and non-responders to Trastuzumab (Tz), to investigate the proteome remodeling associated with acquired resistance to this drug in our 3D cell model. Here, ERBB2 is linked to breast cancer.